{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,15]],"date-time":"2026-11-15T07:24:59Z","timestamp":1794727499391,"version":"4.9.1"},"reference-count":80,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T00:00:00Z","timestamp":1745625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Improved awareness of hemophagocytic lymphohistiocytosis (HLH) among clinicians has led to an increase in its diagnosis. Often diagnosis is made based on the HLH- 2004 criteria. While these criteria have considerable strengths, they lack specificity and may be fulfilled in the setting of many pro-inflammatory disorders. Genetic defects affecting cellular cytotoxicity cause familial (primary) HLH. On the other hand, secondary HLH is more a pathophysiologic process common to many conditions, rather than a singular disease entity. Improved genetic, immunologic, and functional testing have changed not only the way we diagnose HLH, but also how we treat it. In 2004, there were few active agents and regimens. In 2024, there are multiple safe and effective targeted therapies. We have begun to understand that routine and immediate use of etoposide-based therapy in secondary HLH is likely not appropriate, and emerging cytokine-directed therapies may be more rational interventions. Moreover, it is recognized that identifying and treating the driver of secondary HLH is at least as important as treating the cytokine storm and immune dysregulation. Unfortunately, over-reliance on, and narrow interpretation of, the HLH- 2004 criteria can lead to overdiagnosis, misdiagnosis, and unneeded exposure to drugs that can be harmful. It is important that clinicians understand the limitations of the current diagnostic paradigms for secondary HLH, and the shortcomings of reflexive use of etoposide-based therapy. Herein we will discuss the pros and cons of the current paradigm for the recognition, diagnosis, and treatment of secondary HLH.<\/jats:p>","DOI":"10.1186\/s13023-025-03698-0","type":"journal-article","created":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:00:03Z","timestamp":1745640003000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Perspectives on the current diagnostic and treatment paradigms in secondary hemophagocytic lymphohistiocytosis (HLH)"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6312-1307","authenticated-orcid":false,"given":"Leonard","family":"Naymagon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Roehrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle","family":"Hermiston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Connelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Bednarski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaap-Jan","family":"Boelens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanmuganathan","family":"Chandrakasan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blachy","family":"D\u00e1vila Salda\u00f1a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael M.","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prakash","family":"Satwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anish","family":"Ray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelly","family":"Walkovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Teachey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward M.","family":"Behrens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott W.","family":"Canna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,26]]},"reference":[{"key":"3698_CR1","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1182\/asheducation-2013.1.605","volume":"2013","author":"GE Janka","year":"2013","unstructured":"Janka GE, Lehmberg K. Hemophagocytic lymphohistiocytosis: pathogenesis and treatment. Hematol Am Soc Hematol Educ Program. 2013;2013:605\u201311.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"2","key":"3698_CR2","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bjh.14147","volume":"174","author":"E Brisse","year":"2016","unstructured":"Brisse E, Wouters CH, Matthys P. Advances in the pathogenesis of primary and secondary haemophagocytic lymphohistiocytosis: differences and similarities. Br J Haematol. 2016;174(2):203\u201317.","journal-title":"Br J Haematol"},{"issue":"1","key":"3698_CR3","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1586\/eci.09.58","volume":"6","author":"S Gupta","year":"2010","unstructured":"Gupta S, Weitzman S. Primary and secondary hemophagocytic lymphohistiocytosis: clinical features, pathogenesis and therapy. Expert Rev Clin Immunol. 2010;6(1):137\u201354.","journal-title":"Expert Rev Clin Immunol"},{"issue":"2","key":"3698_CR4","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1002\/pbc.21039","volume":"48","author":"JI Henter","year":"2007","unstructured":"Henter JI, Horne A, Arico M, et al. HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2007;48(2):124\u201331.","journal-title":"Pediatr Blood Cancer"},{"issue":"25","key":"3698_CR5","doi-asserted-by":"publisher","first-page":"2728","DOI":"10.1182\/blood-2017-06-788349","volume":"130","author":"E Bergsten","year":"2017","unstructured":"Bergsten E, Horne A, Arico M, et al. Confirmed efficacy of etoposide and dexamethasone in HLH treatment: long-term results of the cooperative HLH-2004 study. Blood. 2017;130(25):2728\u201338.","journal-title":"Blood"},{"key":"3698_CR6","doi-asserted-by":"publisher","first-page":"153321","DOI":"10.1016\/j.prp.2020.153321","volume":"218","author":"L Naymagon","year":"2021","unstructured":"Naymagon L. Can we truly diagnose adult secondary hemophagocytic lymphohistiocytosis (HLH)? A critical review of current paradigms. Pathol Res Pract. 2021;218:153321.","journal-title":"Pathol Res Pract"},{"issue":"5","key":"3698_CR7","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1159\/000514920","volume":"144","author":"L Naymagon","year":"2021","unstructured":"Naymagon L, Tremblay D, Mascarenhas J. The efficacy of etoposide-based therapy in adult secondary hemophagocytic lymphohistiocytosis. Acta Haematol. 2021;144(5):560\u20138.","journal-title":"Acta Haematol"},{"issue":"12","key":"3698_CR8","doi-asserted-by":"publisher","first-page":"e27400","DOI":"10.1002\/pbc.27400","volume":"65","author":"A Gurunathan","year":"2018","unstructured":"Gurunathan A, Boucher AA, Mark M, et al. Limitations of HLH-2004 criteria in distinguishing malignancy-associated hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2018;65(12):e27400.","journal-title":"Pediatr Blood Cancer"},{"issue":"23","key":"3698_CR9","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1182\/blood.2018894618","volume":"133","author":"P La Rosee","year":"2019","unstructured":"La Rosee P, Horne A, Hines M, et al. Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood. 2019;133(23):2465\u201377.","journal-title":"Blood"},{"issue":"1","key":"3698_CR10","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1378\/chest.12-2843","volume":"145","author":"T Rehman","year":"2014","unstructured":"Rehman T, deBoisblanc BP. Persistent fever in the ICU. Chest. 2014;145(1):158\u201365.","journal-title":"Chest"},{"key":"3698_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/9781118869147","volume-title":"Haematology in critical care : a practical handbook","author":"J Thachil","year":"2014","unstructured":"Thachil J, Hill QA. Haematology in critical care\u202f: a practical handbook. Chichester, West Sussex: John Wiley & Sons Ltd.; 2014."},{"issue":"12","key":"3698_CR12","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1097\/01.CCM.0000147769.07699.E3","volume":"32","author":"K Bakhtiari","year":"2004","unstructured":"Bakhtiari K, Meijers JC, de Jonge E, Levi M. Prospective validation of the international society of thrombosis and haemostasis scoring system for disseminated intravascular coagulation. Crit Care Med. 2004;32(12):2416\u201321.","journal-title":"Crit Care Med"},{"issue":"1","key":"3698_CR13","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/S0022-2275(20)38390-5","volume":"30","author":"VG Cabana","year":"1989","unstructured":"Cabana VG, Siegel JN, Sabesin SM. Effects of the acute phase response on the concentration and density distribution of plasma lipids and apolipoproteins. J Lipid Res. 1989;30(1):39\u201349.","journal-title":"J Lipid Res"},{"issue":"4","key":"3698_CR14","first-page":"428","volume":"15","author":"PW Connelly","year":"1999","unstructured":"Connelly PW, Petrasovits A, Stachenko S, MacLean DR, Little JA, Chockalingam A. Prevalence of high plasma triglyceride combined with low HDL-C levels and its association with smoking, hypertension, obesity, diabetes, sedentariness and LDL-C levels in the Canadian population Canadian Heart Health Surveys Research Group. Can J Cardiol. 1999;15(4):428\u201333.","journal-title":"Can J Cardiol"},{"issue":"11","key":"3698_CR15","doi-asserted-by":"publisher","first-page":"e0186674","DOI":"10.1371\/journal.pone.0186674","volume":"12","author":"EC Rotbain","year":"2017","unstructured":"Rotbain EC, Hansen DL, Schaffalitzky O, de Muckadell F, Wibrand AM, Lund HF. Splenomegaly \u2013 diagnostic validity, work-up, and underlying causes. PLOS ONE. 2017;12(11):e0186674. https:\/\/doi.org\/10.1371\/journal.pone.0186674.","journal-title":"PLOS ONE"},{"issue":"2","key":"3698_CR16","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1007\/s12185-015-1813-1","volume":"102","author":"H Saeed","year":"2015","unstructured":"Saeed H, Woods RR, Lester J, Herzig R, Gul Z, Monohan G. Evaluating the optimal serum ferritin level to identify hemophagocytic lymphohistiocytosis in the critical care setting. Int J Hematol. 2015;102(2):195\u20139.","journal-title":"Int J Hematol"},{"issue":"4","key":"3698_CR17","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1111\/ejh.13391","volume":"104","author":"L Naymagon","year":"2020","unstructured":"Naymagon L, Tremblay D, Mascarenhas J. Reevaluating the role of ferritin in the diagnosis of adult secondary hemophagocytic lymphohistiocytosis. Eur J Haematol. 2020;104(4):344\u201351.","journal-title":"Eur J Haematol"},{"issue":"6","key":"3698_CR18","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1002\/pbc.21423","volume":"50","author":"CE Allen","year":"2008","unstructured":"Allen CE, Yu X, Kozinetz CA, McClain KL. Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2008;50(6):1227\u201335.","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"3698_CR19","doi-asserted-by":"publisher","first-page":"2247","DOI":"10.1016\/j.chest.2021.07.056","volume":"160","author":"SM Stevens","year":"2021","unstructured":"Stevens SM, Woller SC, Baumann Kreuziger L, et al. Executive summary: antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report. Chest. 2021;160(6):2247\u201359.","journal-title":"Chest"},{"issue":"5","key":"3698_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1042\/cs0970529","volume":"97","author":"A Takala","year":"1999","unstructured":"Takala A, Jousela I, Jansson SE, et al. Markers of systemic inflammation predicting organ failure in community-acquired septic shock. Clin Sci (Lond). 1999;97(5):529\u201338.","journal-title":"Clin Sci (Lond)"},{"issue":"11","key":"3698_CR21","doi-asserted-by":"publisher","first-page":"e78730","DOI":"10.1371\/journal.pone.0078730","volume":"8","author":"N Yoshida","year":"2013","unstructured":"Yoshida N, Oda M, Kuroda Y, et al. Clinical significance of sIL-2R levels in B-cell lymphomas. PLoS ONE. 2013;8(11):e78730.","journal-title":"PLoS ONE"},{"issue":"4","key":"3698_CR22","first-page":"410","volume":"34","author":"Y Moon","year":"2004","unstructured":"Moon Y, Kim Y, Kim M, et al. Plasma soluble interleukin-2 receptor (sIL-2R) levels in patients with acute leukemia. Ann Clin Lab Sci. 2004;34(4):410\u20135.","journal-title":"Ann Clin Lab Sci"},{"issue":"2","key":"3698_CR23","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1007\/BF02231527","volume":"12","author":"S Sawada","year":"1993","unstructured":"Sawada S, Hashimoto H, Iijma S, et al. Increased soluble IL-2 receptor in serum of patients with systemic lupus erythematosus. Clin Rheumatol. 1993;12(2):204\u20139.","journal-title":"Clin Rheumatol"},{"issue":"8","key":"3698_CR24","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.4049\/jimmunol.141.8.2612","volume":"141","author":"JA Symons","year":"1988","unstructured":"Symons JA, Wood NC, Di Giovine FS, Duff GW. Soluble IL-2 receptor in rheumatoid arthritis. Correlation with disease activity, IL-1 and IL-2 inhibition. J Immunol. 1988;141(8):2612\u20138. https:\/\/doi.org\/10.4049\/jimmunol.141.8.2612.","journal-title":"J Immunol"},{"issue":"3","key":"3698_CR25","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1111\/ejh.13433","volume":"105","author":"L Naymagon","year":"2020","unstructured":"Naymagon L, Tremblay D, Troy K, Mascarenhas J. Soluble interleukin-2 receptor (sIL-2r) level is a limited test for the diagnosis of adult secondary hemophagocytic lymphohistiocytosis. Eur J Haematol. 2020;105(3):255\u201361.","journal-title":"Eur J Haematol"},{"issue":"4","key":"3698_CR26","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/00043426-199611000-00002","volume":"18","author":"RM Egeler","year":"1996","unstructured":"Egeler RM, Shapiro R, Loechelt B, Filipovich A. Characteristic immune abnormalities in hemophagocytic lymphohistiocytosis. J Pediatr Hematol Oncol. 1996;18(4):340\u20135.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"5","key":"3698_CR27","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1182\/blood.2019003664","volume":"136","author":"J Carvelli","year":"2020","unstructured":"Carvelli J, Piperoglou C, Farnarier C, et al. Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect. Blood. 2020;136(5):542\u201352.","journal-title":"Blood"},{"issue":"1","key":"3698_CR28","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1186\/s13023-020-01390-z","volume":"15","author":"J Zhang","year":"2020","unstructured":"Zhang J, Sun Y, Shi X, et al. Genotype characteristics and immunological indicator evaluation of 311 hemophagocytic lymphohistiocytosis cases in China. Orphanet J Rare Dis. 2020;15(1):112.","journal-title":"Orphanet J Rare Dis"},{"issue":"22","key":"3698_CR29","doi-asserted-by":"publisher","first-page":"2993","DOI":"10.1182\/blood-2016-12-753830","volume":"129","author":"TS Rubin","year":"2017","unstructured":"Rubin TS, Zhang K, Gifford C, et al. Perforin and CD107a testing is superior to NK cell function testing for screening patients for genetic HLH. Blood. 2017;129(22):2993\u20139.","journal-title":"Blood"},{"issue":"6","key":"3698_CR30","doi-asserted-by":"publisher","first-page":"1316","DOI":"10.1097\/01.CCM.0000127779.24232.15","volume":"32","author":"R Strauss","year":"2004","unstructured":"Strauss R, Neureiter D, Westenburger B, Wehler M, Kirchner T, Hahn EG. Multifactorial risk analysis of bone marrow histiocytic hyperplasia with hemophagocytosis in critically ill medical patients\u2013a postmortem clinicopathologic analysis. Crit Care Med. 2004;32(6):1316\u201321.","journal-title":"Crit Care Med"},{"issue":"6","key":"3698_CR31","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S0046-8177(88)80177-1","volume":"19","author":"S Suster","year":"1988","unstructured":"Suster S, Hilsenbeck S, Rywlin AM. Reactive histiocytic hyperplasia with hemophagocytosis in hematopoietic organs: a reevaluation of the benign hemophagocytic proliferations. Hum Pathol. 1988;19(6):705\u201312.","journal-title":"Hum Pathol"},{"issue":"9","key":"3698_CR32","doi-asserted-by":"publisher","first-page":"2613","DOI":"10.1002\/art.38690","volume":"66","author":"L Fardet","year":"2014","unstructured":"Fardet L, Galicier L, Lambotte O, et al. Development and validation of the HScore, a score for the diagnosis of reactive hemophagocytic syndrome. Arthritis Rheumatol. 2014;66(9):2613\u201320.","journal-title":"Arthritis Rheumatol"},{"issue":"1","key":"3698_CR33","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s13054-020-02941-3","volume":"24","author":"C Knaak","year":"2020","unstructured":"Knaak C, Nyvlt P, Schuster FS, et al. Hemophagocytic lymphohistiocytosis in critically ill patients: diagnostic reliability of HLH-2004 criteria and HScore. Crit Care. 2020;24(1):244.","journal-title":"Crit Care"},{"issue":"7","key":"3698_CR34","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1182\/blood-2002-01-0172","volume":"100","author":"JI Henter","year":"2002","unstructured":"Henter JI, Samuelsson-Horne A, Arico M, et al. Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation. Blood. 2002;100(7):2367\u201373.","journal-title":"Blood"},{"issue":"5","key":"3698_CR35","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.jaip.2018.05.031","volume":"6","author":"S Ehl","year":"2018","unstructured":"Ehl S, Astigarraga I, von Bahr GT, et al. Recommendations for the Use of Etoposide-Based Therapy and Bone Marrow Transplantation for the Treatment of HLH: Consensus Statements by the HLH Steering Committee of the Histiocyte Society. J Allergy Clin Immunol Pract. 2018;6(5):1508\u201317.","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"1","key":"3698_CR36","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/jha2.57","volume":"1","author":"MC Nicholson","year":"2020","unstructured":"Nicholson MC, Naeije L, Hayden AR, Mattman A, Dix D, Chen LYC. Etoposide\u2010based treatment of adult HLH is associated with high biochemical response but poor survival outcomes. eJHaem. 2020;1(1):277\u201380. https:\/\/doi.org\/10.1002\/jha2.57.","journal-title":"eJHaem"},{"issue":"51","key":"3698_CR37","doi-asserted-by":"publisher","first-page":"e2318","DOI":"10.1097\/MD.0000000000002318","volume":"94","author":"T Barba","year":"2015","unstructured":"Barba T, Maucort-Boulch D, Iwaz J, et al. hemophagocytic lymphohistiocytosis in intensive care unit: A 71-case strobe-compliant retrospective study. Med (Baltimore). 2015;94(51):e2318.","journal-title":"Med (Baltimore)"},{"issue":"1","key":"3698_CR38","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1111\/bjh.13102","volume":"168","author":"M Arca","year":"2015","unstructured":"Arca M, Fardet L, Galicier L, et al. Prognostic factors of early death in a cohort of 162 adult haemophagocytic syndrome: impact of triggering disease and early treatment with etoposide. Br J Haematol. 2015;168(1):63\u20138.","journal-title":"Br J Haematol"},{"issue":"10","key":"3698_CR39","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.clml.2018.06.014","volume":"18","author":"E Apodaca","year":"2018","unstructured":"Apodaca E, Rodriguez-Rodriguez S, Tuna-Aguilar EJ, Demichelis-Gomez R. Prognostic factors and outcomes in adults with secondary hemophagocytic lymphohistiocytosis: a single-center experience. Clin Lymphoma Myeloma Leuk. 2018;18(10):e373\u201380.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"3698_CR40","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.mayocp.2013.12.012","volume":"89","author":"SA Parikh","year":"2014","unstructured":"Parikh SA, Kapoor P, Letendre L, Kumar S, Wolanskyj AP. Prognostic factors and outcomes of adults with hemophagocytic lymphohistiocytosis. Mayo Clin Proc. 2014;89(4):484\u201392.","journal-title":"Mayo Clin Proc"},{"issue":"3","key":"3698_CR41","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjh.13837","volume":"172","author":"AM Schram","year":"2016","unstructured":"Schram AM, Comstock P, Campo M, et al. Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years. Br J Haematol. 2016;172(3):412\u20139.","journal-title":"Br J Haematol"},{"issue":"7","key":"3698_CR42","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1080\/10428194.2020.1737684","volume":"61","author":"RJ Bubik","year":"2020","unstructured":"Bubik RJ, Barth DM, Hook C, et al. Clinical outcomes of adults with hemophagocytic lymphohistiocytosis treated with the HLH-04 protocol: a retrospective analysis. Leuk Lymphoma. 2020;61(7):1592\u2013600.","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3698_CR43","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1111\/j.1651-2227.1991.tb11878.x","volume":"80","author":"JI Henter","year":"1991","unstructured":"Henter JI, Elinder G, Soder O, Ost A. Incidence in Sweden and clinical features of familial hemophagocytic lymphohistiocytosis. Acta Paediatr Scand. 1991;80(4):428\u201335.","journal-title":"Acta Paediatr Scand"},{"key":"3698_CR44","doi-asserted-by":"publisher","first-page":"848004","DOI":"10.3389\/fped.2022.848004","volume":"10","author":"N Balakumar","year":"2022","unstructured":"Balakumar N, Sendi P, Totapally BR. Epidemiology and outcomes of neonatal hemophagocytic lymphohistiocytosis. Front Pediatr. 2022;10:848004.","journal-title":"Front Pediatr"},{"issue":"2","key":"3698_CR45","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3324\/haematol.2018.198655","volume":"104","author":"JH Yoon","year":"2019","unstructured":"Yoon JH, Park SS, Jeon YW, et al. Treatment outcomes and prognostic factors in adult patients with secondary hemophagocytic lymphohistiocytosis not associated with malignancy. Haematologica. 2019;104(2):269\u201376.","journal-title":"Haematologica"},{"key":"3698_CR46","doi-asserted-by":"publisher","first-page":"71","DOI":"10.3389\/fped.2019.00071","volume":"7","author":"WY Kim","year":"2019","unstructured":"Kim WY, Montes-Mojarro IA, Fend F, Quintanilla-Martinez L. Epstein-barr virus-associated T and NK-cell lymphoproliferative diseases. Front Pediatr. 2019;7:71.","journal-title":"Front Pediatr"},{"key":"3698_CR47","doi-asserted-by":"publisher","first-page":"334","DOI":"10.3389\/fped.2018.00334","volume":"6","author":"A Sawada","year":"2018","unstructured":"Sawada A, Inoue M. Hematopoietic stem cell transplantation for the treatment of epstein-barr virus-associated T- or NK-cell lymphoproliferative diseases and associated disorders. Front Pediatr. 2018;6:334.","journal-title":"Front Pediatr"},{"issue":"1","key":"3698_CR48","doi-asserted-by":"publisher","first-page":"e29","DOI":"10.3324\/haematol.2019.220301","volume":"105","author":"JH Liang","year":"2020","unstructured":"Liang JH, Wang L, Zhu HY, et al. Dose-adjusted EPOCH regimen as first-line treatment for non-Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis: a single-arm, open-label, phase II trial. Haematologica. 2020;105(1):e29\u201332.","journal-title":"Haematologica"},{"issue":"7","key":"3698_CR49","doi-asserted-by":"publisher","first-page":"3033","DOI":"10.1007\/s00432-022-04157-0","volume":"149","author":"Y Pi","year":"2023","unstructured":"Pi Y, Wang J, Zhou H, et al. Modified DEP regimen as induction therapy for lymphoma-associated hemophagocytic lymphohistiocytosis: a prospective, multicenter study. J Cancer Res Clin Oncol. 2023;149(7):3033\u201341.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"3698_CR50","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1007\/s00277-022-04946-0","volume":"101","author":"L Chen","year":"2022","unstructured":"Chen L, Wang J, Wang Z. L-DEP regimen is effective as an initial therapy for adult EBV-HLH. Ann Hematol. 2022;101(11):2461\u201370.","journal-title":"Ann Hematol"},{"issue":"19","key":"3698_CR51","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1182\/blood-2015-05-644914","volume":"126","author":"Y Wang","year":"2015","unstructured":"Wang Y, Huang W, Hu L, et al. Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood. 2015;126(19):2186\u201392.","journal-title":"Blood"},{"issue":"9","key":"3698_CR52","doi-asserted-by":"publisher","first-page":"3463","DOI":"10.1007\/s00277-024-05796-8","volume":"103","author":"D Yin","year":"2024","unstructured":"Yin D, Wang J, Wang Z. The effectiveness of the doxorubicin-etoposide-methylprednisolone regimen for adult HLH secondary to rheumatic disease. Ann Hematol. 2024;103(9):3463\u201372.","journal-title":"Ann Hematol"},{"issue":"6","key":"3698_CR53","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1309\/AJCP4ZDKJ4ICOUAT","volume":"139","author":"FG Rosado","year":"2013","unstructured":"Rosado FG, Kim AS. Hemophagocytic lymphohistiocytosis: an update on diagnosis and pathogenesis. Am J Clin Pathol. 2013;139(6):713\u201327.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"3698_CR54","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1182\/hematology.2023000463","volume":"2023","author":"A Kumar","year":"2023","unstructured":"Kumar A, Cournoyer E, Naymagon L. Inflamed-HLH, MAS, or something else? Hematol Am Soc Hematol Educ Program. 2023;2023(1):31\u20136.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"15","key":"3698_CR55","doi-asserted-by":"publisher","first-page":"4041","DOI":"10.1182\/blood-2011-03-278127","volume":"118","author":"MB Jordan","year":"2011","unstructured":"Jordan MB, Allen CE, Weitzman S, Filipovich AH, McClain KL. How I treat hemophagocytic lymphohistiocytosis. Blood. 2011;118(15):4041\u201352.","journal-title":"Blood"},{"issue":"7","key":"3698_CR56","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1182\/blood.2021012764","volume":"139","author":"A Zoref-Lorenz","year":"2022","unstructured":"Zoref-Lorenz A, Murakami J, Hofstetter L, et al. An improved index for diagnosis and mortality prediction in malignancy-associated hemophagocytic lymphohistiocytosis. Blood. 2022;139(7):1098\u2013110.","journal-title":"Blood"},{"issue":"5","key":"3698_CR57","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/BOR.0000000000000526","volume":"30","author":"S Yasin","year":"2018","unstructured":"Yasin S, Schulert GS. Systemic juvenile idiopathic arthritis and macrophage activation syndrome: update on pathogenesis and treatment. Curr Opin Rheumatol. 2018;30(5):514\u201320.","journal-title":"Curr Opin Rheumatol"},{"issue":"5","key":"3698_CR58","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1093\/intimm\/dxy012","volume":"30","author":"GS Schulert","year":"2018","unstructured":"Schulert GS, Canna SW. Convergent pathways of the hyperferritinemic syndromes. Int Immunol. 2018;30(5):195\u2013203.","journal-title":"Int Immunol"},{"issue":"6","key":"3698_CR59","doi-asserted-by":"publisher","first-page":"857","DOI":"10.1136\/ard-2022-223739","volume":"82","author":"F De Benedetti","year":"2023","unstructured":"De Benedetti F, Grom AA, Brogan PA, et al. Efficacy and safety of emapalumab in macrophage activation syndrome. Ann Rheum Dis. 2023;82(6):857\u201365.","journal-title":"Ann Rheum Dis"},{"issue":"24","key":"3698_CR60","doi-asserted-by":"publisher","first-page":"2469","DOI":"10.1182\/blood.2021011898","volume":"138","author":"DA Lichtenstein","year":"2021","unstructured":"Lichtenstein DA, Schischlik F, Shao L, et al. Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells. Blood. 2021;138(24):2469\u201384.","journal-title":"Blood"},{"issue":"23","key":"3698_CR61","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1056\/NEJMra2026131","volume":"383","author":"DC Fajgenbaum","year":"2020","unstructured":"Fajgenbaum DC, June CH. Cytokine storm. N Engl J Med. 2020;383(23):2255\u201373.","journal-title":"N Engl J Med"},{"issue":"2","key":"3698_CR62","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1182\/blood.2019001333","volume":"134","author":"MS Zinter","year":"2019","unstructured":"Zinter MS, Hermiston ML. Calming the storm in HLH. Blood. 2019;134(2):103\u20134.","journal-title":"Blood"},{"issue":"6","key":"3698_CR63","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1016\/j.jpeds.2011.11.046","volume":"160","author":"X Xiao-Jun","year":"2012","unstructured":"Xiao-Jun X, Tang Y-M, Song H, Yang S-L, Wei-Qun X, Zhao N, Shi S-W, Shen H-P, Mao J-Q, Zhang L-Y, Pan B-H. Diagnostic accuracy of a specific cytokine pattern in hemophagocytic lymphohistiocytosis in children. J Pediatrics. 2012;160(6):984-990.e1. https:\/\/doi.org\/10.1016\/j.jpeds.2011.11.046.","journal-title":"J Pediatrics"},{"issue":"6","key":"3698_CR64","doi-asserted-by":"publisher","first-page":"e358","DOI":"10.1016\/S2665-9913(20)30096-5","volume":"2","author":"P Mehta","year":"2020","unstructured":"Mehta P, Cron RQ, Hartwell J, Manson JJ, Tattersall RS. Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. Lancet Rheumatol. 2020;2(6):e358\u201367.","journal-title":"Lancet Rheumatol"},{"issue":"1","key":"3698_CR65","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1186\/s13054-020-02878-7","volume":"24","author":"E Dufranc","year":"2020","unstructured":"Dufranc E, Del Bello A, Belliere J, Kamar N, Faguer S. group Ts IL6-R blocking with tocilizumab in critically ill patients with hemophagocytic syndrome. Crit Care. 2020;24(1):166.","journal-title":"Crit Care"},{"issue":"21","key":"3698_CR66","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1182\/blood.2019002289","volume":"134","author":"M Vallurupalli","year":"2019","unstructured":"Vallurupalli M, Berliner N. Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis. Blood. 2019;134(21):1783\u20136.","journal-title":"Blood"},{"issue":"12","key":"3698_CR67","doi-asserted-by":"publisher","first-page":"e630","DOI":"10.1016\/S2352-3026(19)30156-5","volume":"6","author":"A Ahmed","year":"2019","unstructured":"Ahmed A, Merrill SA, Alsawah F, et al. Ruxolitinib in adult patients with secondary haemophagocytic lymphohistiocytosis: an open-label, single-centre, pilot trial. Lancet Haematol. 2019;6(12):e630\u20137.","journal-title":"Lancet Haematol"},{"issue":"5","key":"3698_CR68","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1097\/PCC.0000000000000078","volume":"15","author":"S Rajasekaran","year":"2014","unstructured":"Rajasekaran S, Kruse K, Kovey K, et al. Therapeutic role of anakinra, an interleukin-1 receptor antagonist, in the management of secondary hemophagocytic lymphohistiocytosis\/sepsis\/multiple organ dysfunction\/macrophage activating syndrome in critically ill children*. Pediatr Crit Care Med. 2014;15(5):401\u20138.","journal-title":"Pediatr Crit Care Med"},{"issue":"2","key":"3698_CR69","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","volume":"50","author":"PM Miettunen","year":"2011","unstructured":"Miettunen PM, Narendran A, Jayanthan A, Behrens EM, Cron RQ. Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients. Rheumatology. 2011;50(2):417\u20139.","journal-title":"Rheumatology"},{"issue":"12","key":"3698_CR70","doi-asserted-by":"publisher","first-page":"e736","DOI":"10.1016\/S2665-9913(20)30361-1","volume":"2","author":"A Kavirayani","year":"2020","unstructured":"Kavirayani A, Charlesworth JEG, Segal S, et al. The Lazarus effect of very high-dose intravenous anakinra in severe non-familial CNS-HLH. Lancet Rheumatol. 2020;2(12):e736\u20138.","journal-title":"Lancet Rheumatol"},{"issue":"11","key":"3698_CR71","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.28581","volume":"67","author":"S Bami","year":"2020","unstructured":"Bami S, Vagrecha A, Soberman D, et al. The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis. Pediatr Blood Cancer. 2020;67(11): e28581.","journal-title":"Pediatr Blood Cancer"},{"issue":"12","key":"3698_CR72","doi-asserted-by":"publisher","first-page":"1775","DOI":"10.1016\/j.annonc.2020.08.2101","volume":"31","author":"BC Ozdemir","year":"2020","unstructured":"Ozdemir BC, Latifyan S, Perreau M, et al. Cytokine-directed therapy with tocilizumab for immune checkpoint inhibitor-related hemophagocytic lymphohistiocytosis. Ann Oncol. 2020;31(12):1775\u20138.","journal-title":"Ann Oncol"},{"issue":"8","key":"3698_CR73","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","volume":"23","author":"RQ Le","year":"2018","unstructured":"Le RQ, Li L, Yuan W, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor t cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943\u20137.","journal-title":"Oncologist"},{"issue":"4","key":"3698_CR74","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.chest.2020.06.006","volume":"158","author":"CC Price","year":"2020","unstructured":"Price CC, Altice FL, Shyr Y, et al. Tocilizumab treatment for cytokine release syndrome in hospitalized patients with coronavirus disease 2019: survival and clinical outcomes. Chest. 2020;158(4):1397\u2013408.","journal-title":"Chest"},{"issue":"5","key":"3698_CR75","doi-asserted-by":"publisher","first-page":"e210","DOI":"10.3324\/haematol.2019.222471","volume":"105","author":"J Wang","year":"2020","unstructured":"Wang J, Wang Y, Wu L, et al. Ruxolitinib for refractory\/relapsed hemophagocytic lymphohistiocytosis. Haematologica. 2020;105(5):e210\u20132.","journal-title":"Haematologica"},{"issue":"1","key":"3698_CR76","doi-asserted-by":"publisher","first-page":"234","DOI":"10.3324\/haematol.2022.281221","volume":"108","author":"G Stalder","year":"2023","unstructured":"Stalder G, Suffiotti M, Segot A, et al. Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial. Haematologica. 2023;108(1):234\u20139.","journal-title":"Haematologica"},{"issue":"3","key":"3698_CR77","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1016\/S2352-3026(21)00366-5","volume":"9","author":"A Setiadi","year":"2022","unstructured":"Setiadi A, Zoref-Lorenz A, Lee CY, Jordan MB, Chen LYC. Malignancy-associated haemophagocytic lymphohistiocytosis. Lancet Haematol. 2022;9(3):e217\u201327.","journal-title":"Lancet Haematol"},{"issue":"19","key":"3698_CR78","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","volume":"382","author":"F Locatelli","year":"2020","unstructured":"Locatelli F, Jordan MB, Allen C, et al. Emapalumab in children with primary hemophagocytic lymphohistiocytosis. N Engl J Med. 2020;382(19):1811\u201322.","journal-title":"N Engl J Med"},{"issue":"9","key":"3698_CR79","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1182\/bloodadvances.2023012217","volume":"8","author":"S Chandrakasan","year":"2024","unstructured":"Chandrakasan S, Jordan MB, Baker A, et al. Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab. Blood Adv. 2024;8(9):2248\u201358.","journal-title":"Blood Adv"},{"issue":"4","key":"3698_CR80","doi-asserted-by":"publisher","first-page":"558","DOI":"10.3390\/healthcare11040558","volume":"11","author":"H Althobaiti","year":"2023","unstructured":"Althobaiti H, Seoane-Vazquez E, Brown LM, Fleming ML, Rodriguez-Monguio R. Disentangling the cost of orphan drugs marketed in the united states. Healthcare. 2023;11(4):558.","journal-title":"Healthcare"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03698-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-025-03698-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-025-03698-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T05:02:16Z","timestamp":1745643736000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-025-03698-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,26]]},"references-count":80,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3698"],"URL":"https:\/\/doi.org\/10.1186\/s13023-025-03698-0","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,26]]},"assertion":[{"value":"24 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"LN has no conflicts to disclose. PR has served on advisory board for SOBI. MH has served on advisory board for SOBI. JC has served on advisory board for SOBI. JB is advisor to Horizon Therapeutics, SOBI, and Prime Medicine. JJB is a consultant for Bluebird Bio, Avrobio, Bluerock, Omeros, Equillium, Sanofi, Medexus, and SOBI. SC has served on advisory board for SOBI. BDS has served on advisory board for SOBI. MMH has served on advisory board for SOBI. PS is a consultant for SOBI, Takeda, Mesoblast, and Atara Biotherapeutics. AR has served on an advisory board for SOBI. KW is on the advisory board for Pharming, Horizon Pharma, and AstraZeneca, on the steering committee for SOBI, and local PI for a clinical trial conducted by X4 Pharma. DT serves on advisory boards for SOBI, Janssen, and BEAM Therapeutics, receives research funding from BEAM Therapeutics and NeoImmune Tech, has patents pending for biomarkers for cytokine release syndrome and CD38 CART for hematologic malignancies. EMB has served on advisory board for SOBI. SWC is a consultant for AB2 Bio, IMMvention Therapeutix, Johnson and Johnson, Novartis, Simcha, and SOBI. AK is a consultant and speaker for SOBI.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}